MedPharm’s Technical Expertise Expands the Potential Applications of Products
MedPharm’s performance testing models help to support client’s to understand the potential applications of their products
MedPharm’s unique expertise to model the behaviour of pharmaceutical formulations using ex vivo human tissue has helped clients’ expand the potential applications of their products. Examples of this have been published recently in the Journal of Dermatological Treatment and presented at the 3rd German Pharm-Tox Summit.
One paper published in the Journal of Dermatology Treatment entitled “In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails” describes the use of MedPharm’s proprietary TurChub® model, to evaluate the diffusion and subsequent activity of drugs in human nails for the treatment of onychomycosis (T. rubrum) MedPharm’s scientists were able to show that the application of nail polish to the nail had no impact on the ability of the drug to penetrate or kill the fungal infection. If you would like to learn more about this experiment please click here to read the full article.
In the poster at the 3rd German Pharm-Tox Summit this year entitled “Determination of the permeation and penetration of Flurbiprofen from a locally acting sore throat lozenge and spray into human pharynx tissue” MedPharm scientists compared the penetration of Flurbiprofen into ex vivo human larynx tissue when delivered by spray or lozenge. In both cases it was demonstrated that there was rapid and deep drug penetration. This provides strong support that both treatments can provide quick acting relief.
Dr Rob Turner, MedPharm’s VP of Business Development & Innovation, commented, “MedPharm has twenty years of experience in modelling the behaviour of formulated drugs using skin and other ex vivo human tissue in the laboratory. These examples are just two ways in which our models can be employed to expand the clinical applicability of a product. MedPharm is continuously investing in research to increase the sophistication of it’s models.”
“We routinely use fresh healthy ex vivo human skin to monitor the biological activity of many drug candidates as well as their penetration and permeation,” added Dr Jon Lenn, MedPharm’s Chief Technology Officer. “We can maintain the viability of the skin up to 10 days in the laboratory which greatly increases the options we have for monitoring and optimising both drug and drug product performance.”
Notes to editors
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.